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ABSTRACT
Objective: To assess the relationship between serum osteocalcin and periodontal clinical attachment loss (CAL) in postmenopausal women in relation 
to their osteoporosis risk status.
Methods: A cross-sectional study was carried out on 71 postmenopausal women in Kenari District, Central Jakarta, Indonesia. The periodontal 
examination for all the subjects included a CAL measurement. The serum osteocalcin level was analyzed using ELISA.
Results: The correlation between the serum osteocalcin level in patients with CAL and the risk of osteoporosis was analyzed with the Spearman test. 
The normal group had 29 subjects (40.84%), the osteopenic group had 23 subjects (32.39%), and the osteoporotic group had 19 subjects (26.76%). 
There was a significant correlation between CAL and the osteoporosis high-risk status (p<0.05) and no significant correlation between the serum 
osteocalcin level and the osteoporosis status (p>0.05).
Conclusion: No correlation was found between CAL and the serum osteocalcin level (p>0.05).
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INTRODUCTION
Osteoporosis is defined as a bone disease characterized by a decrease 
in bone mass and alterations in microarchitecture that result in bone 
fragility and an increased risk of fractures in the future [1]. Osteoporosis 
results from an imbalance between the rates of bone formation and 
resorption, which leads to the loss of bone mineral mass [2]. Based 
on data from the international osteoporosis foundation in 2013, the 
prevalence of osteoporosis in Indonesian women aged 50–80 years old 
is 23% and in those aged 70–80 years is 53%. By 2050, one-third of the 
total population will be at high risk for osteoporosis [3].
Periodontitis is a destructive inflammatory disease of the tooth-
supporting structures and is a major cause of tooth loss. Its presence is 
determined by the measurement of clinical attachment loss (CAL) [4]. 
The etiology of this disease is periodontal pathogens found in dental 
plaque that results in the inflammation of the tooth-supporting 
structure [2]. Periodontal diseases are correlated with several 
systemic diseases such as cardiovascular diseases, diabetes mellitus, 
osteoporosis, respiratory diseases, and others [5].
Both osteoporosis and periodontitis are bone-destroying diseases. 
They are characterized by increased bone resorption, host dependence, 
a multifactorial etiology, and stimulated by cytokine activity [4]. The 
relationship between osteoporosis and periodontal diseases is one 
of the bidirectional interferences. The reduction in bone mineral 
density in osteoporosis alters the trabecular pattern and may lead 
to a more rapid jawbone resorption caused by periodontal disease, 
due to the invasion of periodontal pathogenic bacteria. Conversely, 
the invasion of periodontal pathogenic bacteria may alter the normal 
homeostasis of the alveolar bone, increasing the osteoclastic activity 
and reducing the local and systemic bone density [6]. Pepelasi 
et al. [7] suggested that postmenopausal women with osteoporosis 
had greater gingival inflammation, periodontal attachment loss, and 
gingival recession than postmenopausal women with a normal bone 
mineral density (BMD).
The American Academy of Periodontology suggested that osteoporosis 
is not an etiology for periodontal disease but that it can exaggerate 
alveolar bone destruction [8]. Postmenopausal women with a 
reduced BMD have a greater tendency for alveolar bone loss and 
CAL because inflammatory mediators are increased in the systemic 
and oral bones [9]. Bone turnover can be assessed by measurements 
of a protein produced by osteoblasts and osteoclasts: Osteocalcin, 
also known as the bone Gla protein, which is a noncollagenous bone 
protein [10].
Noncollagenous bone matrix proteins play a key role in matrix 
mineralization, cellular adhesion, and the regulation of cell activity 
during the coupling of bone formation and resorption. Osteocalcin, 
one of the most abundant of these proteins, plays a key role in 
mineralization, may act as a chemoattractant, and may be essential for 
osteoclast differentiation [11]. It is synthesized mainly by osteoblasts as 
well as a small number of odontoblasts and chondroblasts. After being 
synthesized, it is stored in the bone mineral matrix as hydroxyapatite 
crystals and is recognized as a marker of bone formation [10]. Serum 
osteocalcin is known to be a valid biomarker for detecting a low 
BMD [12].
Increases in serum osteocalcin levels are associated with rapid bone 
loss. In osteoporosis, there is a deficiency of the calcium level and since 
osteocalcin is known as a calcium-dependent biomarker and has a 
strong affinity with hydroxyapatite responsible for bone mineralization. 
Osteoporosis leads to decreased hydroxyapatite crystal formation, and 
hence, results in an increase in serum osteocalcin levels [13].
To the best of our knowledge, there have been no studies analyzing 
the association between serum osteocalcin and periodontal status in 
Research Article
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2017.v9s2.22
International workshop on Dental Research hosted by Faculty of Dentistry Universitas Indonesia, Jakarta, 2017
International workshop on Dental Research hosted by Faculty of Dentistry Universitas Indonesia, Jakarta, 2017 93
Int J App Pharm, Vol 9, Special Issue 2, 2017
 Hutomo et al. 
postmenopausal women with osteoporosis in Indonesia. The objective 
of this study was to assess the relationship of serum osteocalcin and 
periodontal CAL levels with the risk of osteoporosis in postmenopausal 
women.
METHODS
A cross-sectional study was carried out in 71 postmenopausal women 
ranging in age from 48 to 87 years in the Kenari District, Central Jakarta, 
Indonesia. The inclusion criteria were women who had already had 
menopause for at least 1 year from their last menstrual period, who 
still had natural teeth in their maxilla and mandible, who were able 
to communicate, and who were willing to participate in this study. 
The exclusion criteria were women with systemic diseases, who were 
former smokers and alcoholics, who had received hormone therapy 
within the past 5 years, and who had had a hysterectomy. This study 
was approved by the Ethical Committee of the Faculty of Dentistry, 
Universitas Indonesia. All of the subjects signed informed consent 
forms before joining this study.
The risk of osteoporosis was determined by the mandibular bone 
density index. This index determines the risk of osteoporosis in subjects 
by assessing their age, duration of menopause, body mass index, history 
of hormonal therapy, duration of daily sun exposure, daily activity, 
and calcium intake. The subjects were classified into three groups: 
Osteoporosis (high risk), osteopenia (medium risk), and normal (low 
or no risk). A score from −9 to 25 meant osteoporosis, 26–52 meant 
osteopenia, and 53–95 was normal [14].
A periodontal examination was carried out for all subjects, and the 
following measurements were recorded to determine the level of CAL. 
CAL was measured from the cement-enamel junction to the base of 
the pocket using a periodontal probe. All of the measurements were 
assessed at six sites per tooth: Mesiobuccal, midbuccal, distobuccal, 
mesiolingual, midlingual, and distolingual.
A syringe was used to draw 5 mL of venous blood, which was then 
centrifuged for 10 min. The samples were stored in small capped vials 
for long-term use at −20°C until tested. The serum was examined by 
the ELISA method, performed at Laboratorium Terpadu, Faculty of 
Medicine, Universitas Indonesia, Jakarta.
The data were analyzed using SPSS software from IBM. A normality test 
was performed. The correlations of age, serum osteocalcin level, and 
CAL with the osteoporosis risk were tested using a Spearman correlation 
test. Only p<0.05 was considered to be statistically significant, and a 
positive value showed a positive correlation. Comparison of serum 
osteocalcin levels with severity of CAL was tested using Kruskal-Wallis 
test.
RESULTS
Seventy-one postmenopausal women ranging in age from 48 to 87 
years participated in this study. The subjects were classified into 
three groups: Normal, with 29 subjects (40.28%); osteopenia, with 23 
subjects (31.94%); and osteoporosis, with 19 subjects (26.39%). The 
mean values of the serum osteocalcin level and CAL for all three groups 
are presented in Table 1. The osteoporosis group had a higher mean 
age, mean serum osteocalcin level, and mean CAL than the other groups.
To investigate the correlations between the serum osteocalcin and 
CAL levels and the osteoporosis risk, the data were analyzed with a 
Spearman correlation test. Table 2 summarizes that there was a positive 
correlation between CAL and the osteoporosis high-risk status (r=0.32; 
p<0.05), but there was no correlation between serum osteocalcin levels 
and the osteoporosis risk (p>0.05).
Table 3 summarizes that there was no difference in the osteocalcin 
levels among subjects with mild, moderate, and severe CAL. The serum 
osteocalcin level was higher in those with mild and moderate CAL than 
with severe CAL. These results suggest that there is no statistically 
significant difference in the serum osteocalcin levels of the subjects 
with mild, moderate, and severe CAL (p>0.05).
DISCUSSION
This study was conducted in postmenopausal women because there 
is a strong relationship between menopause and osteoporosis. In 
postmenopausal women, hormonal changes cause an increase in 
receptor activator of nuclear factor Kappa-B ligand (RANKL), as 
does osteoclast activity. As a consequence, there is a shift from bone 
remodeling toward bone resorption that leads to osteoporosis [15].
The World Health Organization has determined that dual-energy X-ray 
absorptiometry is the gold standard for diagnosing osteoporosis. In 
this study, we used a questionnaire that determined the subjects’ risk 
factors for osteoporosis (the mandibular bone density index) [14].This 
method was used because the index was developed based on a scoring 
model that consists of risk factors for osteoporosis. The index has a 
sensitivity of 77.06% and a specificity of 78.45% [14].
In individuals with osteoporosis, a low BMD in the jawbones may be 
associated with low systemic bone density. This low bone density or 
loss of bone density may lead to an increased susceptibility to the 
resorption of alveolar bone in areas with periodontitis. Systemic factors 
also modify the response of local tissue to periodontal infection and 
may also affect bone remodeling. Individuals with systemic bone loss 
have an increased systemic production of proinflammatory cytokines 
that may affect bone, including the maxilla and mandible. The result is 
a low bone density in the jawbones, caused by the increase in alveolar 
porosity, and more rapid alveolar bone resorption following an invasion 
by periodontal pathogens [16].
Bone remodeling occurs throughout the human lifespan. Bone is 
renewed by the bone turnover process, the products of which are known 
as bone turnover biomarkers and are classified as bone formation 
biomarkers and bone resorption biomarkers. Osteoblasts produce 
osteocalcin, which is important for calcification [17]. Serum osteocalcin 
is presently considered to be a valid marker of bone turnover when 
resorption and formation are coupled and a specific marker of bone 
formation when formation and resorption are uncoupled. Osteocalcin 
may be involved in recruiting osteoclasts to the sites of newly formed 
bone and thus may function as a negative regulator [18].
Table 1 summarizes that there is a tendency for serum osteocalcin 
levels and CAL to be higher in postmenopausal women with a high 
risk of osteoporosis than in the normal and osteopenia groups. 
Elevated serum osteocalcin levels have been found during periods 
of rapid bone turnover, as seen in osteoporosis, multiple myeloma, 
Table 1: Characteristics of the three groups of subjects
Postmenopausal woman Mean (SD)
Normal (n=29) Osteopenia (n=23) Osteoporosis (n=19)
Age (years) 56.55 (7.86) 62.26 (6.34) 66 (6.81)
Serum osteocalcin (ng/mL) 0.87 (0.94) 0.86 (1.23) 1.03 (1.32)
CAL (mm) 2.56 (0.81) 3.28 (0.94) 3.38 (1.32)
SD: Standard deviation, CAL: Clinical attachment loss
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and fracture repair [13]. Osteocalcin can be used as a marker of bone 
formation to give an idea about the change in bone turnover when it 
is normalized with respect to resorption [19]. Osteocalcin plays a role 
in bone resorption and the mineralization process, and it is involved in 
osteoclast recruitment to the sites of bone resorption and formation so 
that it may function as negative regulator [18].
The relationship between periodontal disease and osteoporosis is still 
controversial, but in this study, we suggest that there is a relationship 
between these diseases. Table 2 summarizes that CAL was positively 
correlated with osteoporosis high-risk status (p=0.01, r=0.32), meaning 
that osteoporosis subjects had greater tendency toward higher CAL than 
the osteopenia or normal subjects. This finding is similar to that of a study 
conducted by Pepelassi et al., [7] which showed that osteoporotic women 
had significantly greater CAL, and severe periodontitis was most frequent 
among osteoporotic women. A similar result was reported in a systematic 
review by Dodd et al. [9] of the five longitudinal studies reviewed, four 
showed an association between osteoporosis and periodontal disease, 
20 of 25 cross-sectional studies demonstrated a relationship between 
the two diseases, and all three case–control studies also showed an 
association. In contrast to this study, Masulili et al. [20] showed that there 
was no significant relationship between CAL and BMD.
Table 3 summarizes that there was no statistically significant 
association between the serum osteocalcin levels and the severity 
of CAL (p=0.31). This finding is similar to that of a study conducted 
by Bullon et al. [21] showing that there was no difference in CAL 
with regard to serum osteocalcin levels but suggesting that CAL was 
correlated with gingival crevicular fluid (GCF) and saliva osteocalcin 
levels. Osteocalcin is produced by osteoblasts and secreted directly 
into the blood in small amounts. Serum osteocalcin may not be a 
determinant of the periodontal status, as opposed to the osteocalcin 
in GCF and saliva because the serum levels reflect the bone turnover 
condition in whole bone.
The limitation of this study is that the no-risk, osteopenia risk, and 
osteoporosis risk groups of subjects were not equal in size. Subjects 
with a high osteoporosis risk were only a quarter of the total sample. 
However, this proportion was similar to the distribution of the 
osteoporosis prevalence in Indonesia. To get a better result, the author 
suggests a larger sample size in future research.
CONCLUSION
The results of this study showed no correlation of serum osteocalcin 
levels and periodontal attachment loss with osteoporosis risk in 
postmenopausal women, but serum osteocalcin levels were higher 
in the osteoporosis group than in the normal and osteopenia groups. 
There is a positive correlation between periodontal attachment loss 
and osteoporosis high-risk status.
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Age 71 0.56* 0.001*
Serum osteocalcin 0.01 0.92
CAL 0.32* 0.01*
Spearman test, *p<0.05 significance. CAL: Clinical attachment loss
Table 3: Comparison of serum osteocalcin levels in subjects with 
different severities of CAL
Severity of CAL Osteocalcin (ng/mL) mean (SD) p
Mild (1–2 mm) 0.63 (0.45) 0.31
Moderate (3–4 mm) 1.33 (1.63)
Severe (≥5 mm) 0.61 (0.37)
Kruskal–Wallis test, p<0.05 significance. CAL: Clinical attachment loss
